Audit: QRS - Pantothenic Acid for Health & Longevity

Audit conducted on 22/08/2026 06:14 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (600 → 900 mg/day, 2.2 g/day, 5 mg/day), time windows, biomarker targets, benefit and risk items trace to ER Therapeutic Protocol, Practical Considerations, Monitoring Protocol & Defining Success, Expected Benefits, and Potential Risks & Side Effects.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“(theoretical caution)”, “(investigational only)”, “None clinically significant”, and “may reduce their uptake” mirror the ER’s own hedges in Key Interactions & Contraindications.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication qualifiers (“confirmed on patch testing”, “until the cause is established”) and the deficiency caveat (“only where intake is genuinely inadequate”) are carried at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list, Key Interactions from the ER interaction bullets, Benefits/Risks from their own tiered ER sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS; named drugs (atorvastatin, donepezil, clopidogrel, etc.) are generic names taken from the same ER bullets.
1.6	The QRS does not introduce new attributions.	🟢	No new sources, experts, or organisations are named.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER, including its scepticism about industry funding and the “energy vitamin” claim.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dose regimens are presented alongside plain-language framing without hype.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively; no imperatives directed at a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocols and cadences are reported as the regimens used in the trials, not prescribed; the footer disclaimer is intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommended”, “should take”, or “advised”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker and drug names that have no plain equivalent.
2.8	Information is presented in a concise and very compact manner	🟢	Every list item is a single short clause; no multi-sentence entries.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the rendered content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Apolipoprotein B targets, whole-blood pantothenate assay, and opportunity-cost risk framing address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Three-times-daily dosing with meals, 12-16 week windows, and specialist assays are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified consumer framing or “easy win” language.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The Medium risk entry names under-treated apolipoprotein B as the material hazard, the risk-aware audience’s real exposure.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“gastrointestinal upset”, “allergic contact dermatitis”, “eosinophilia”); the plain wording in At-A-Glance is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Diff against [qrs_template] shows every fixed heading, gate heading, tier label, and column header byte-identical to the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# spans are expanded to 8 marker rows and 5 qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff confirms the only altered lines are the metadata block and the variable spans covered by sections 5-15; website="evidence_review", website="full_review", and website="audit" spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All eight Key Interaction labels and all three Protocol labels (“Integrative lipid approach with pantethine”, “Acne protocol”, “Nutritional baseline”) match the ER bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names match the ER biomarker table verbatim; no ER-supplied label is altered.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; the ER’s “⚠️ Conflicted” marker is correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to single-clause entries; no section carries ER prose, magnitudes, or citations.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2-14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed into the header or footer beyond the template-mandated date and model.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: pantothenic_acid_2026-0822-0432_Opus_ER.md, matching the actual ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching this guideline’s version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0822-0527.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: pantothenic_acid_2026-0822-0432_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Pantothenic Acid for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Pantothenic Acid for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0822-0527 → “08/22/2026”.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the template subline; no alternate-names line despite the ER listing seven.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the four load-bearing points of the ER Conclusion: ubiquity, feedback capping, pantethine’s lipid effect, and the funding caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence of the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “blood fats”, “a related compound”, “levels in muscle”; no acronyms and no clinical-register vocabulary.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year, or sample size named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only the qualitative “modestly” is used; no percentages or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All three items come from the ER’s “Populations who should avoid Pantothenic Acid” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All three ER avoidance bullets are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Three well-formed <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s em-dash clause “— oral pantothenic acid maintained active hand eczema in one such patient” is stripped, as is the tolerable-upper-intake aside.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(Type IV)”, the 1,500 cells/mm³ threshold, and the 90-day window are all retained; only the ER’s plain-language glossary parentheses are dropped.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names avoidance populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map one-to-one to the ER’s eight interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the three contraindication items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight well-formed <li> elements with bold ER labels.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic rationale (“Calcium … chelates”), mitigation advice (“Separation of doses by at least 2 hours”), and re-test instructions are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs and the severity classes “(theoretical caution)” and “(investigational only)” are preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Pantethine lipid regimen (the Medium-tier benefit), acne regimen (the only randomised trial dose), and the nutritional Adequate Intake baseline.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine fields carry ER-derived labels, doses, and qualifiers; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Deficiency correction, lipids, and acne are the only three time-to-effect statements the ER makes (Practical Considerations).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the benefit tiers: deficiency correction (High), lipids (Medium), acne (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Days to weeks”, “4-16 weeks”, and “12 weeks” with ER-derived subtexts.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every tier maps to the corresponding ER benefit headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ER’s two Medium headings are merged into one clause; magnitudes (4-11%, 67%) and qualifiers (“at Gram-Level Doses”) are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry ER content, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every tier maps to the corresponding ER risk headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier reduced to short clauses; the ER’s statin comparison figures and case-report details are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry ER content, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Markers, targets, and rationales come from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarker rows are present in the same order with matching targets.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 8 and 16 weeks, then every 6-12 months, plus the 12-week acne checkpoint — matching the ER’s second monitoring paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER’s “Qualitative markers worth tracking alongside the labs” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present in the same order.

Issues 22/08/2026 06:14

Pass rate 100.00%. No issues found.

Issues 22/08/2026 06:08

1. 1.3 — OTC claim strengthened: Line 555 states “None documented with analgesics, antihistamines, antacids”, dropping “clinically significant” from the ER’s “No clinically significant interactions are documented with analgesics, antihistamines, or antacids” (ER line 308) and thereby widening the claim.
2. 2.8 — Redundant time-to-effect sub: Line 489’s [time_1_sub] “Genuine deficiency resolves within days to weeks” restates [time_1_value] “Days to weeks” (line 486) and the label “Deficiency correction” (line 483) without adding information.

Fixes 22/08/2026 06:08

1. 1.3 — OTC claim strengthened: Restored the ER’s qualifier in the Over-the-counter medications interaction, changing “None documented with analgesics, antihistamines, antacids” to “None clinically significant with analgesics, antihistamines, antacids”.
2. 2.8 — Redundant time-to-effect sub: Replaced [time_1_sub] “Genuine deficiency resolves within days to weeks”, which merely restated the value and label, with “Symptom resolution, only where intake is genuinely inadequate” (ER, Expected Benefits: “applies only where intake is genuinely inadequate”).

Issues 22/08/2026 06:01

1. 9.4 — Key Interaction items not fully condensed: Line 554 appends “; none reported clinically” to the severity class, and line 559 says “under study, not contraindicated (investigational only)” where “not contraindicated” restates the parenthetical — both are elaborations beyond the key fact.
2. 1.1 — Truncated urinary marker rationale: marker_5_why (line 650) reads “Reflects recent intake where no blood assay”, dropping the verb from the ER’s “Reflects recent intake where blood assay is unavailable” (ER line 442) and leaving an ungrammatical fragment.

Fixes 22/08/2026 06:01

1. 9.4 — Key Interaction items condensed: Trimmed the cholinesterase-inhibitor item from “(theoretical caution; none reported clinically)” to “(theoretical caution)”, and the checkpoint-inhibitor item from “under study, not contraindicated (investigational only)” to “under study (investigational only)”.
2. 1.1 — Urinary marker rationale completed: Changed marker_5_why from “Reflects recent intake where no blood assay” to “Reflects recent intake where no blood assay is available”, restoring the verb dropped from the ER wording.

Issues 22/08/2026 05:54

1. 1.2 / 1.3 — Hedge dropped in At-A-Glance: The ER Conclusion (line 475) hedges the mechanism as “this appears to be why large doses fail to raise levels inside muscle”, but [at_a_glance] (QRS line 433) asserts it flatly as “so large doses fail to raise levels in muscle”, strengthening a hedged ER claim.

Fixes 22/08/2026 05:54

1. 1.2 / 1.3 — At-A-Glance hedge restored: Changed “Cells cap their own production once supply is plentiful, so large doses fail to raise levels in muscle” to “… which appears to be why large doses fail to raise levels in muscle”, matching the ER Conclusion’s hedged phrasing. The section remains within the 60-word limit.

Issues 22/08/2026 05:46

1. 9.5 — Dose qualifier dropped from interaction: The antiplatelet/anticoagulant [caution_items] entry at QRS line 558 names “fish oil” where the ER (line 314) specifies “high-dose fish oil”; the dose threshold that determines whether the interaction applies to a given reader was not preserved.

Fixes 22/08/2026 05:46

1. 9.5 — Restored fish oil dose qualifier: In the antiplatelet/anticoagulant [caution_items] entry, “fish oil” was changed to “high-dose fish oil” to match the ER’s qualifier.

Issues 22/08/2026 05:40

1. 4.5 — Content overruns the one-page budget: At the A4 print width the sheet renders to roughly twice the available height; the Key Interactions gate (lines 552-559) alone wraps to about 27 lines, and Benefits, Risks, At-A-Glance, the monitoring cadence and the qualitative list all carry near-verbatim ER wording instead of being condensed to their per-section budget.

Fixes 22/08/2026 05:40

1. 4.5 — Key Interactions gate condensed: Rewrote all eight caution_items to their key fact while retaining every ER bold label and named drug list, e.g. “Calcium pantothenate reduces absorption of doxycycline…” to “Reduced absorption of doxycycline…”, cutting the gate from roughly 27 wrapped lines to about 19.
2. 4.5 — Contraindications trimmed: Dropped the redundant “Documented” and “has been identified / is established” wording from the first and third stop_items, keeping the Type IV, 1,500 cells/mm³, and 90-day qualifiers intact.
3. 4.5 — At-A-Glance shortened: Reduced from 59 to 56 words (“found in” to “present in”, “throttle” to “cap”, “unusually favorable” to “favorable”), removing one wrapped line from the largest-type block on the sheet.
4. 4.5 — Benefits and Risks tiers condensed: Stripped residual qualifiers and mechanistic tails (“at gram-level doses”, “systemic contact reactions”, “through raised acetyl-coenzyme A”, “by coenzyme A repletion”) and shortened the Medium benefit to “LDL cholesterol”, cutting seven benefit lines to four and eight risk lines to four.
5. 4.5 — Protocol and Time to Effect subs shortened: Tightened action_1_sub, action_2_sub, time_1_sub, time_2_sub, and time_3_sub to single-clause form, e.g. “Correcting a genuine deficiency resolves symptoms within days to weeks” to “Genuine deficiency resolves within days to weeks”.
6. 4.5 — Monitoring and Qualitative compacted: Shortened marker_5_why, marker_7_target, monitoring_cadence, qualitative_item_1, and qualitative_item_5 so each renders on one line, removing three two-line table rows and the cadence overflow.

Issues 22/08/2026 05:33

1. 12.3 — Redundant qualifier in Medium benefits: [benefits_medium] at line 525 states “with the pantethine form” twice (“Lower low-density lipoprotein cholesterol and apolipoprotein B with the pantethine form; lower triglycerides with the pantethine form”), which is not as concise as possible.

Fixes 22/08/2026 05:33

1. 12.3 — Redundant qualifier in Medium benefits: Merged the two Medium benefit clauses into one, from “Lower low-density lipoprotein cholesterol and apolipoprotein B with the pantethine form; lower triglycerides with the pantethine form” to “Lower low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides with the pantethine form”.